The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company Vertex Pharmaceuticals on Thursday. The drug, which is called suzetrigine ...

Protesters took to the streets of lower Manhattan to denounce and protest U.S. Immigration and Customs Enforcement (ICE) on ...

The Summerlin master-planned community offers more than 75 unique floor plans in 15 neighborhoods throughout eight distinct ...

At the recent 210mm Five-Year Ecological Innovation Conference, Dr. Zhang Yingbin, Head of Strategy, Product, and Marketing at Trinasolar, took the stage to highlight the transformative impact of the ...

When Takeda CEO Christophe Weber retires from the company in June 2026, a familiar face among the Massachusetts biotech scene will take over leading the Japanese pharma giant.

Also, higher bond yields Friday weighed on stocks.  Bond yields rose Friday after the US Jan unemployment rate unexpectedly fell to an 8-month low, and Jan average hourly earnings rose more than ...

The firm could possibly eye about $800 million for the second continuation fund. Others that have adopted this strategy include Vertex Holdings and technology investment firm Basil Partners, which was ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...